Dissolution of metastatic thymic carcinoma-associated right atrial thrombus with rivaroxaban.
Curlene NimbletteRajeev SeecheranJessica KawallValmiki SeecheranSangeeta PersadKoomatie RamsaroopNaveen Anand SeecheranPublished in: SAGE open medical case reports (2020)
Thymic carcinoma typically exhibits more clinically aggressive behavior and portends a worse prognosis as compared to thymoma. Venous thromboembolism is a significant cause of morbidity and mortality in oncologic patients. Traditionally, the standard-of-care management of cancer-associated venous thromboembolism has been therapeutic anticoagulation with low molecular weight heparins; however, with the advent of direct oral anticoagulants, there is an ongoing paradigm shift to transition to these novel agents in an attempt to attenuate cancer-associated venous thromboembolism events. We describe an exceedingly rare case of metastatic thymic carcinoma-associated right atrial thrombus with high-risk embolic features, which subsequently underwent near-complete dissolution with rivaroxaban after 3 months.
Keyphrases
- venous thromboembolism
- direct oral anticoagulants
- rare case
- atrial fibrillation
- end stage renal disease
- squamous cell carcinoma
- small cell lung cancer
- ejection fraction
- chronic kidney disease
- healthcare
- left atrial
- newly diagnosed
- palliative care
- prostate cancer
- quality improvement
- prognostic factors
- catheter ablation
- rectal cancer
- patient reported
- affordable care act
- health insurance
- mitral valve